Lilly Announces Acquisition of Hypnion Deal shall bolster Lilly's Sleep Disorder Research with promising insomnia compound
07 Mar 2007 -
Eli Lilly and Company and Hypnion, Inc. announced that they have signed a definitive merger agreement whereby Lilly will acquire Hypnion, a privately held neuroscience drug discovery company focused on sleep disorders. The transaction has received the requisite approval of Hypnion stockholders and is expected to close near the end of the first quarter of 2007, contingent upon clearance under the Hart-Scott-Rodino
Anti-Trust Improvements Act and other customary closing conditions. Financial terms of the deal were not disclosed.
Additional information
Eli Lilly and Company Indianapolis, Indiana, United States of America
Top
Print version
PDF version
Send article
RSS feed